|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,951.50 INR | +0.46% |
|
+3.35% | +13.48% |
| 09:53am | Sun Pharma Wins South Africa Approval for Generic Semaglutide | MT |
| 07-10 | India's Dr Reddy's posts worst week in 3 years as semaglutide setback stokes growth fears | RE |
| Market Cap | 4,682B 48.75B 42.6B 39.38B 36.38B 68.52B 69.76B 470B 184B 2,293B 183B 179B 7,895B | P/E 2027 * |
35.5x | P/E 2028 * | 30x |
|---|---|---|---|---|---|
| Enterprise Value | 4,409B 45.9B 40.11B 37.08B 34.26B 64.52B 65.69B 442B 174B 2,159B 172B 169B 7,434B | EV / Sales 2027 * |
6.74x | EV / Sales 2028 * | 5.95x |
| Free-Float |
44.39% | Yield 2027 * |
0.82% | Yield 2028 * | 0.91% |
Last Transcript: Sun Pharmaceutical Industries Ltd.
| 1 day | +0.46% | ||
| 1 week | +3.35% | ||
| Current month | +4.78% | ||
| 1 month | +8.06% | ||
| 3 months | +15.02% | ||
| 6 months | +16.93% | ||
| Current year | +13.48% |
| 1 week | 1,888.2 |  | 1,962.7 |
| 1 month | 1,792.6 | | 1,962.7 |
| Current year | 1,583.7 | | 1,962.7 |
| 1 year | 1,548 | | 1,962.7 |
| 3 years | 1,063.85 | | 1,962.7 |
| 5 years | 672.55 | | 1,962.7 |
| 10 years | 312 | | 1,962.7 |
| Manager | Title | Age | Since |
|---|---|---|---|
Aalok Shanghvi
CEO | Chief Executive Officer | - | - |
| Chief Executive Officer | 59 | 01/09/2025 | |
| Director of Finance/CFO | 58 | 01/07/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 70 | - | |
| Director/Board Member | 59 | 01/09/2025 | |
| Director/Board Member | 73 | 25/05/2018 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.46% | +3.35% | +12.97% | +81.10% | 48.52B | |
| -0.36% | -1.79% | +66.39% | +111.26% | 35.68B | |
| -0.01% | +0.43% | -3.55% | +39.25% | 12.09B | |
| +2.06% | +0.78% | +19.56% | +91.84% | 11.77B | |
| +1.13% | +0.38% | +32.83% | +126.50% | 9.19B | |
| -1.81% | -4.04% | +43.76% | -5.22% | 7.06B | |
| -0.50% | -0.25% | +18.61% | +37.23% | 7.01B | |
| -0.33% | +3.31% | +3.20% | +227.08% | 6.77B | |
| +3.56% | -6.15% | -20.01% | +13.39% | 5.98B | |
| +1.33% | +5.35% | +28.04% | +140.96% | 4.43B | |
| Average | +0.56% | -0.22% | +20.18% | +86.34% | 14.85B | |
| Weighted average by Cap. | +0.36% | -0.53% | +26.61% | +88.14% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 654B 6.81B 5.95B 5.5B 5.08B 9.57B 9.74B 65.6B 25.74B 320B 25.58B 25.01B 1,103B | 729B 7.59B 6.64B 6.13B 5.67B 10.67B 10.87B 73.15B 28.7B 357B 28.52B 27.89B 1,230B |
| Net income | 133B 1.38B 1.21B 1.12B 1.03B 1.94B 1.98B 13.3B 5.22B 64.93B 5.19B 5.07B 224B | 157B 1.63B 1.42B 1.32B 1.22B 2.29B 2.33B 15.7B 6.16B 76.67B 6.12B 5.99B 264B |
| Net Debt | -273B -2.84B -2.49B -2.3B -2.12B -4B -4.07B -27.4B -10.75B -134B -10.68B -10.45B -461B | -341B -3.55B -3.11B -2.87B -2.65B -5B -5.09B -34.25B -13.44B -167B -13.35B -13.06B -576B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 15/07/26 | ₹1,951.50 | +0.46% | 2,283,494 |
| 14/07/26 | ₹1,942.60 | +1.10% | 2,822,124 |
| 13/07/26 | ₹1,921.40 | -0.73% | 1,573,176 |
| 10/07/26 | ₹1,935.50 | -0.17% | 1,478,172 |
| 09/07/26 | ₹1,938.70 | +2.67% | 4,446,201 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- SUNPHARMA Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
